TL;DR
This paper provides a comprehensive "map" of the last decade of melatonin research in the context of insomnia, using bibliometric visualization tools to analyze over 1,000 studies. It highlights a significant shift in the field: moving from general sleep-aid studies toward targeted clinical applications for vulnerable populations—specifically children, the elderly, and those with complex comorbidities like cancer and neurodevelopmental disorders.
What Problem Does This Paper Address?
While melatonin is one of the most studied and widely used supplements for sleep, the sheer volume of research makes it difficult for clinicians and scientists to identify overarching trends, key collaborators, or emerging "hotspots."
The authors address this fragmentation by performing a bibliometric analysis. This isn't just a literature review; it’s a quantitative and visual deep dive into the "meta-data" of science. They sought to answer: Who are the leading contributors? Which institutions are driving the field? And most importantly, how have the research themes evolved from 2015 to 2024?
Methods
The researchers utilized two powerful bibliometric software tools to parse data from the Web of Science Core Collection (WoSCC) and PubMed:
- VOSviewer (v1.6.20): Used primarily to visualize collaborative networks. It creates maps where the distance between "nodes" (countries, authors, or journals) represents the strength of their relationship.
- CiteSpace (v6.3 R1): Employed to detect "citation bursts" and keyword co-occurrence. This helps identify exactly when a specific topic (like "gut-brain axis") suddenly became a focal point for the scientific community.
The study followed a PRISMA-style screening process, narrowing down 1,818 initial results to a final set of 1,084 high-quality original articles and reviews.
Datasets
The study relied on two primary global research databases:
- Web of Science Core Collection (WoSCC): Provided 1,314 initial records.
- PubMed: Provided 504 initial records.
The authors specifically looked for literature published between January 1, 2015, and December 31, 2024. (Note: The paper's metadata lists a 2025 publication date, likely reflecting the "early access" or forward-dated nature of the journal's current volume).
Key Insights and Ideas
- The Three Phases of Growth: Research didn't grow linearly. The authors identified a "slow start" (2015–2018), a "steady rise" (2019–2021), and a "peak phase" (2022–2024). This suggests that melatonin’s role in clinical medicine is currently in a period of high-intensity exploration.
- Volume vs. Influence: While the United States leads in total publication volume (300 papers) and total citations (8,153), Germany holds the highest average citation rate (46.02). This indicates that while the US produces the most work, German research in this niche tends to have a very high per-paper impact.
- From "Sleep Aid" to "Circadian Regulator": A major thematic shift is occurring. Researchers are moving away from viewing melatonin as a simple sedative and toward treating it as a "circadian rhythm regulator." This has led to increased interest in the suprachiasmatic nucleus (SCN) and the gut-brain axis.
- The Comorbidity Convergence: The most significant "aha moment" in the data is the convergence of insomnia research with other fields. Melatonin is increasingly being studied not just for sleep, but for its secondary benefits in oncology (reducing chemotherapy side effects) and neurology (managing symptoms of Alzheimer’s and Parkinson’s).
Key Results
- Top Institution: Harvard Medical School is the most influential institution, ranking first in total citations (692) and having a high average citation rate.
- Leading Author: Bruni O. is the most prolific author (17 publications), focusing heavily on pediatric insomnia and neurodevelopmental disabilities.
- Journal Dominance: Sleep Medicine is the most prolific journal, while Sleep Medicine Reviews carries the highest prestige with an Impact Factor of 11.2.
- Keyword Bursts: "Autism spectrum disorder" (intensity 3.36) and "neurodevelopmental disorders" (intensity 3.54) showed the strongest citation bursts, signaling a massive research pivot toward using melatonin in children with ASD and ADHD.
- Trend Equation: The authors calculated a linear trend line ($Y = 11.964X - 24052$) with an $R^2$ of 0.9283, confirming a statistically strong upward trajectory for the field.
Limitations and Future Work
The authors acknowledge several constraints:
- Language Bias: By only including English-language publications, the study may have overlooked significant regional research, particularly from China, which ranked second in total publication volume.
- Database Limitations: The exclusion of databases like Scopus or Embase might have missed some relevant literature.
- Co-authorship Analysis: The study focused on institutional and national collaborations but did not deeply analyze individual researcher-to-researcher relationships.
Future Directions: The paper suggests that the next decade of research will likely focus on the "multi-target intervention" strategy—integrating melatonin into broader treatment plans for chronic pain, cancer-related fatigue, and the management of the gut microbiota.
Summary updated